GT
RYTM icon

Glenmede Trust’s Rhythm Pharmaceuticals RYTM Stock Holding History

Glenmede Trust’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-50
Closed -$1K – 2045
2020
Q3 		$1K Hold
50
– – ﹤0.01% 2390
2020
Q2 		$1K Buy
+50
New +$975 ﹤0.01% 2366

Other funds holding RYTM

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

Glenmede Trust's RYTM Position: Q4 2020 in Review

Glenmede Trust sold out of Rhythm Pharmaceuticals (RYTM) in Q4 2020, closing a stake of 50 shares — an estimated $1K sold.

Glenmede Trust first reported a position in RYTM in Q2 2020 and held it in 2 quarters. The position peaked at $1K in Q3 2020. 119 funds tracked by Wall St. Rank hold RYTM as of Q4 2020.

  • Glenmede Trust reported no remaining Rhythm Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Glenmede Trust sold 50 Rhythm Pharmaceuticals shares in Q4 2020, an estimated $1K.
  • Glenmede Trust first reported a position in Rhythm Pharmaceuticals in Q2 2020 and held it in 2 quarters.
  • Glenmede Trust's Rhythm Pharmaceuticals position peaked at $1K in Q3 2020.
  • 119 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q4 2020.

Based on Glenmede Trust's 13F filing for Q4 2020, filed 16 Feb 2021.